A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00540358. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multi-center, Open-Label, Randomized Trial of Gemcitabine/ Carboplatin, With or Without BSI-201, in Patients With ER, PR and HER2-negative Metastatic Breast Cancer
Study identification
- NCT ID
- NCT00540358
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 123 participants
Conditions and interventions
Conditions
Interventions
- gemcitabine/carboplatin Drug
- iniparib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2007
- Primary completion
- Oct 31, 2009
- Completion
- May 31, 2010
- Last update posted
- Dec 27, 2012
2007 – 2010
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | — | — |
| Research Site | Denver | Colorado | — | — |
| Research Site | Torrington | Connecticut | — | — |
| Research Site | Ocoee | Florida | — | — |
| Research Site | Indianapolis | Indiana | — | — |
| Research Site | Overland Park | Kansas | — | — |
| Research Site | Henderson | Nevada | — | — |
| Research Site | Hooksett | New Hampshire | — | — |
| Research Site | Raleigh | North Carolina | — | — |
| Research Site | Bedford | Texas | — | — |
| Research Site | Dallas | Texas | — | — |
| Research Site | El Paso | Texas | — | — |
| Research Site | Fort Worth | Texas | — | — |
| Research Site | Houston | Texas | — | — |
| Research Site | Tyler | Texas | — | — |
| Research Site | Fairfax | Virginia | — | — |
| Research Site | Vancouver | Washington | — | — |
| Research Site | Yakima | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00540358, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 27, 2012 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00540358 live on ClinicalTrials.gov.